Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NicOx ophthalmology strategy back on course after Altacor shrug-off

This article was originally published in Scrip

Executive Summary

NicOx has licensed one marketed and two development-stage ocular diagnostic tests from Rapid Pathogen Screening. It is building its own commercial organisation in the US and Europe to market AdenoPlus, RPS's rapid point-of-care diagnostic tear sample-based test for adenoviral conjunctivitis, which is authorised for marketing in the US and EU. The company hopes to acquire or in-license additional ophthalmology products, diagnostic and therapeutic, to market through the same infrastructure in future.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017839

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel